Edgar Filing: Epizyme, Inc. - Form 4

Epizyme, In Form 4	nc.								
September	15, 2014								
FOR	ЛЛ							PPROVAL	
	UNITED	STATES SECU W		AND EXCHA , D.C. 20549	NGE C	COMMISSIO	N OMB Number:	3235-0287	
Check t if no lo subject Section Form 4 Form 5 obligati may co	to 16. or Filed put ions Section 17(MENT OF CHA rsuant to Section (a) of the Public	SECUI	RITIES ne Securities E	e Act of 1934,	Estimated burden hou response	urs per		
<i>See</i> Ins 1(b).		30(h) of the	Investmen	t Company Ac	et of 194	0			
(Print or Type	e Responses)								
1. Name and Address of Reporting Person <u>*</u> Ho Peter Tai-Ching			2. Issuer Name and Ticker or Trading Symbol Epizyme, Inc. [EPZM]			5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First) (Middle) 3. Date	3. Date of Earliest Transaction			(Check all applicable)			
C/O EPIZ TECHNO	(Month	(Month/Day/Year) 09/11/2014			Director 10% Owner X_ Officer (give title Other (specify below) below) Chief Development Officer				
			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person			
	DGE, MA 02139					Person	More than One R	eporting	
(City)	(State)	(Zip) Ta	ble I - Non-	Derivative Secur	rities Acq	uired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8)	4. Securities onAcquired (A) or Disposed of (D) (Instr. 3, 4 and 5 (A) or Amount (D)	r So) B 5) O Fo R T	Amount of ecurities eneficially wned ollowing eported ransaction(s) nstr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Ro	eport on a separate line	e for each class of se	curities bene	Persons wi information required to	ho respo n contair o respond	ndirectly. and to the colle ned in this form d unless the fo y valid OMB co	n are not orm	SEC 1474 (9-02)	
				number.	currenti				

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date 3A. Dee	med 4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year) Execution	on Date, if Transac	tiorDerivative	Expiration Date	Underlying Securities
Security	or Exercise	any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: Epizyme, Inc. - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	8)	Acquired (A Disposed o (Instr. 3, 4, 5)	f (D)				
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 28.2	09/11/2014		A		150,000		(1)	09/10/2024	Common Stock	150,000

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Ho Peter Tai-Ching C/O EPIZYME, INC. 400 TECHNOLOGY SQUARE CAMBRIDGE, MA 02139			Chief Development Officer				
Signatures							
/s/ Stephen Garbacz, attorney-in-fact	0	9/15/2014					

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This option was granted on September 11, 2014 pursuant to the Company's 2013 Stock Incentive Plan with respect to 150,000 shares of
(1) Common Stock, with 25% vesting on September 11, 2015 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.